Shownotes
Was testosterone replacement non-inferior to placebo for cardiovascular safety in men with hypogonadism and high cardiovascular risk?
In TRAVERSE, testosterone replacement was non-inferior to placebo for major adverse cardiac events in middle-aged and older men with hypogonadism and high cardiovascular risk.
Randomised trial · New England Journal of Medicine 2023
Reference: Lincoff AM, Bhasin S, Flevaris P, et al. N Engl J Med. 2023;389(2):107-117. PMID: 37326322. https://pubmed.ncbi.nlm.nih.gov/37326322/
AI-narrated episode. For healthcare professionals; educational only and not medical…
Website: listen.hubhopper.com

